Gynecologic cancers often present at advanced stages and can be difficult to treat effectively. HRD status is a key biomarker in ovarian and related gynecologic cancers, and timely identification with HRD testing via CGP can significantly improve patient outcomes.
Together, we can close gaps in care, empower clinicians, and improve outcomes for women and families across our region and beyond.
Thank you for your support
$500
Purpose Investments Inc.
$104
Allyson Walton
Allison birthday gift
$100
Ryan Stewart
$52
Blair Richards
$104
Sheri Morgan
Happy birthday Allyson Watson!
$26
Natalie Watson
🎈
$104
Shannon Fitzpatrick
$500
Peakhill Capital
$500
Michelle Yates
$350




